Introduction: Community-acquired pneumonia (CAP) is a significant contributor to illness and hospitalization among children worldwide. Pediatric CAP continues to provide a challenge to clinicians, despite considerable progress in medical research and immunization initiatives, owing to its varied origin, symptomatology that overlaps with other respiratory illnesses, and evolving microbial patterns. This review aims to (1) consolidate existing knowledge on the etiology and pathogenesis of pediatric CAP, (2) critically assess the significance of emerging biomarkers and diagnostic instruments in clinical decision-making, and (3) delineate modern treatment strategies and preventive measures to enhance patient outcomes. Methods: From scientific articles published over the last 10 years in different scientific platforms, including PubMed, Scopus, Web of Science, and Google Scholar, potentially relevant literature was compiled to update on biomarkers and innovative diagnostic tools for pediatric CAP. Results: In pediatric CAP, microbial pathogenesis is a critical background metric. Eight biomarkers, including C-reactive protein (CRP), procalcitonin (PCT), the neutrophil-to-lymphocyte ratio (NLR), serum amyloid A (SAA), and S100 proteins, have been reviewed with new diagnostic algorithms and instruments to assess disease severity and prognosis. Discussion: To demonstrate the current status of pediatric CAP diagnosis and therapy, seventeen clinical studies have been included. By integrating clinical expertise and developing efficient treatment strategies, this study offers a comprehensive perspective on improving outcomes for children with CAP. Conclusion: Understanding the disease's context is crucial for treatment, research, and prevention. In addition to minimizing diagnostic ambiguity, antibiotic usage, antimicrobial resistance, and biomarker roles and clinical value in pediatric CAP must be addressed.
Yachana Mishra (Tue,) studied this question.